Current opinion on optimal treatment choices in first-line therapy for advanced or metastatic colorectal cancer: Report from the adelaide colorectal tumour group meeting; Stockholm, Sweden; September 2008

Clinical Colorectal Cancer

Volumn 9, Issue 1, 2010, Pages 8-14

  Price, Timothy J ^a   Tebbutt, Niall C ^b   Karapetis, Christos S ^c   Segelov, Eva ^d   Pavlakis, Nick ^e   Cunningham, David ^f   Sobrero, Alberto F ^g   Haller, Daniel G ^h   Shapiro, Jeremy D ⁱ  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b AUSTIN HEALTH   (Australia)

^c FLINDERS MEDICAL CENTRE   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e ROYAL NORTH SHORE HOSPITAL   (Australia)

^f ROYAL MARSDEN HOSPITAL   (United Kingdom)

^g UNIVERSITY OF GENOA   (Italy)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ CABRINI INSTITUTE   (Australia)

Author keywords

5 Fluorouracil; Bevacizumab; Capecitabine; Cetuximab; KRAS; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; VASCULOTROPIN;

ADVANCED CANCER; AGE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; COMORBIDITY; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG SAFETY; GENE MUTATION; HUMAN; HYPERTENSION; INOPERABLE CANCER; KARNOFSKY PERFORMANCE STATUS; METASTASIS; MONOTHERAPY; ONCOGENE K RAS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; SWEDEN; THROMBOEMBOLISM;

EID: 77149128980     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2010.n.001     Document Type: Review

References (52)

1. Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005; 23:9441-9442
2. Poston GJ, Figueras J, Giuliante F, et al. Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol 2008; 26:4828-4833
3. Goldberg RM, Rothenberg ML, Van CE, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 2007; 12:38-50.
4. Cassidy J, Clarke S, Díaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26:2006-2012
5. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005; 23:4866-4875
6. Seymour MT, Maughan TS, Ledermann JA, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007; 370:143-152
7. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-237
8. Colon Cancer. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology-v.2.2008. Available at: http://www.nccn.org. Accessed: November 24, 2009.
9. Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006; 94:798-805.
10. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25:1670-1676
11. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342
12. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26:2013-2019
13. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25:1539-1544
14. Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 2006; 33(suppl 10):S26-34.
15. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626-1634
16. Bokemeyer C, Bondarenko I, Hartman JT, et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol 2008; 26(15 suppl):178s (abstract 4000).
17. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357:2040-2048
18. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757-1765
19. Van Cutsem E, Lang I, D'Haens G, et al. KRAS status and efficacy in the CRYSTAL study: 1st-line treatment of patients with metastatic colorectal cancer (mCRC) receiving FOLFIRI with or without cetuximab. Ann Oncol 2008; 19(suppl 8):viii44 (abstract 71O).
20. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27:672-680
21. Punt CJ, Tol J, Rodenburg CJ, et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 2008; 26(15 suppl):180s (abstract LBA4011).
22. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:2311-2319
23. Di Nicolantonio F, Martini M, Molinari F. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26:5705-5712
24. Langer C, Kopit J, Awad M, et al. Analysis of K-RAS mutations in patients with metastatic colorectal cancer receiving cetuximab in combination with irinotecan: Results from the EPIC trial. Ann Oncol 2008; 19(suppl 8):viii133 (abstract 385P).
25. Ince WL, Jubb AM, Holden SN, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005; 97:981-989
26. Frattini M, Saletti P, Romagnani E, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007; 97:1139-1145
27. Rosen O, Yi J, Hurwitz H, Ince W, et al. Clinical benefit of bevacizumab (BV) in metastatic colorectal cancer (mCRC) is independent of K-RAS mutation status: exploratory analyses in a large placebo-controlled phase III study of previously untreated patients. Ann Oncol 2008; 19(suppl 6):vi19 (abstract O-035).
28. Adam R, Lucidi V, Bismuth H. Hepatic colorectal metastases: methods of improving resectability. Surg Clin North Am 2004; 84:659-671
29. Bilchik AJ, Poston G, Curley SA, et al. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol 2005; 23:9073-9078
30. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240:644-657
31. Folprecht G, Grothey A, Alberts S, et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16:1311-1319
32. Watkins DJ, Jackson C, Chua Y, et al. A prospective study of oxaliplatin and capecitabine (CapOx) in metastatic colorectal cancer (MCRC) with baseline stratification according to resectability status. J Clin Oncol 2007; 25(18 suppl):169s (abstract 4024).
33. Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005; 23:9243-9249
34. De La Cámara J, Rodriguez J, Rotellar F, et al. Triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil and folinic acid within a combined modality approach in patients with liver metastases from colorectal cancer. Proc Am Soc Clin Oncol 2004; 22(14 suppl):268a (abstract 3593).
35. Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004; 15:933-939
36. Ychou M, Viret F, Kramar A, et al. Tritherapy with fluorouracil/ leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol 2008; 62:195-201.
37. Welsh FK, Tilney HS, Tekkis PP, et al. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer 2007; 96:1037-1042
38. Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatinbased chemotherapy for colorectal liver metastases. Cancer 2007; 110:2761-2767
39. Cassidy J, Cunningham D, Berry SR, et al. Surgery with curative intent in patients (pts) treated with first-line chemotherapy (CT) + bevacizumab (BEV) for metastatic colorectal cancer (mCRC): First BEAT and NO16966. J Clin Oncol 2008; 26(15 suppl):183s (abstract 4022).
40. On behalf of the First BEAT investigators, Cunningham D, Kretzschmar A, et al. Efficacy and safety of surgery with curative intent in patients treated with first-line bevacizumab for mCRC: First BEAT. Paper presented at: the 2008 ASCO Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, Florida. Abstract 445.
41. Reddy SK, Morse MA, Hurwitz HI, et al. Addition of bevacizumab to irinotecan-and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 2008; 206:96-106.
42. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005; 91:173-180
43. Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007; 370:135-142
44. Schmoll HJ, Sargent D. Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard? Lancet 2007; 370:105-107
45. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23:3502-3508
46. Cassidy J, Giantonio B, Kabbinavar F, et al. Effect of bevacizumab in patients over 65 years of age with metastatic colorectal cancer (mCRC). Ann Oncol 2008; 19(suppl 8):viii125 (abstract 356P).
47. Kabbinavar F, Irl C, Zurlo A, et al. Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk. Oncology 2008; 75:215-223
48. Price T, Gebski V, van Hazel GA, et al. International multi-centre randomised Phase II/III study of Capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for metastatic colorectal cancer (mCRC): Final safety analysis of the AGITG MAX trial. J Clin Oncol 2008; 26(15 suppl):185s (abstract 4029).
49. Eklund JW, Trifilio S, Mulcahy MF. Chemotherapy dosing in the setting of liver dysfunction. Oncology (Williston Park) 2005; 19:1057-1063
50. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343-2351
51. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adhuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27:3109-3116
52. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25:2198-2204